// App-Quantinova.ai

395 : Patient stratification and drug combination strategy based on drug response and genomic information from PDX clinical trials (PCTs)

Researchers

Presenter

  • Jingjing Jiang

Principal Investigators

  • Tengfei Yu

  • Ying Yan

  • Wei Du

  • Tingting Tan

  • Xuqin Yang

  • Jiali Gu

  • Xin K. Ye

  • Zhenyu Gu

Medical Centers

  • GenenDesign USA, Menlo Park, CA

  • GenenDesign, Shanghai, China

Locations

  • United States

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastric Cancer

  • Lung Cancer

  • Melanoma

  • Solid malignancies

Biomarkers

  • Anaplastic lymphoma Kinase

  • B-Raf proto-oncogene, serine/threonine kinase

  • Breakpoint Cluster Region

  • Epidermal growth factor receptor

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved